February 22, 2023
The development strategy of FSUE "Endopharm" until 2025 includes the implementation of 25 investment projects, 11 of which imply combined financing at the expense of the federal budget and the Enterprise funds, 14 – exclusively at the expense of the Enterprise own funds.
The investment projects implemented by FSUE "Endopharm" jointly with the Ministry of Industry and Trade of the Russian Federation are a part of the program of national security organization in the field of providing citizens of the Russian Federation with centrally acting domestic analgesics and other medicines included in the List of Vital and Essential Drugs.
In 2022, FSUE "Endopharm" completed the implementation of 4 projects.
The Center for the Development of Biotechnological and Innovative Medicines in the "Lefortovskii" branch was put into operation, and its tasks include the development and improvement of the manufacturing technologies of active pharmaceutical ingredients (API) and high-tech medicinal products.
The "Pochep" branch has 3 sites intended for scaling and transfer of API manufacturing technologies developed by the scientific divisions of the Enterprise, as well as for low-tonnage API manufacture. A new laboratory building equipped with high-tech equipment, with the ability to conduct more than 30 thousand studies per year, started to function.
The "ENDOPHARM Agro" branch has implemented a strategically important project for culturing and processing of plant raw materials for the manufacture of opium analgesics and primary processing of food-grade poppy seeds.
In February 2023, the main administrative building of FSUE "Endopharm", located on Novokhokhlovskaya Street, replaced the sign on the roof of the administrative building: the name "Moscow Endocrine Plant" was replaced with the short name "Endopharm", which combines all manufacturing sites of the Enterprise. A media facade is being built on the face of the same building, which is necessary for advertising purposes of its own products and promotion of the Enterprise brand.
Thanks to the commissioning of new high-tech laboratories, administrative and warehouse facilities, the Enterprise will be able to accelerate the development of new substances and medicines of various presentations, improve the quality of logistic services and optimize their cost.
"The facility with an area of more than 6.2 thousand square meters is equipped with modern analytical and testing industrial equipment, including the same of domestic manufacture. Currently, commissioning and other works are being completed to prepare for its commissioning," commented the Deputy Director General – Director of the "Lefortovskii" branch of FSUE "Endopharm" Dmitrii Averyanov.
Comment type is not specified in the component properties.